🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

With the New Year comes new growth and (in our case) new lab and office space! We are delighted to have expanded our research, progressing our mission to develop disease-modifying therapeutics for patients. The Oxford Trust theoxfordtrust.co.uk/samsara-therap…

Snapshot of our recent #teambuilding day. A continuous learning culture contributes to our core values here at Samsara.

The development of dopaminergic neurons 🧠 Swipe to learn more about the cells properties on Day 30 ➡️

Ever wonder what our neuroscientists Gabriela Vilema Enríquez and Matthew Williamson get up to? Find out here: lnkd.in/eKwh4njd

“We are faced with a gigantic medical need, and scientific challenges, which require the use of new tools to carry out translational research.” Hear Samsara's VP of Translational Medicine Géraldine Farjot voicing our research commitments. challenges.fr/economie/samsa…

At Samsara Therapeutics we see autophagy as a potential therapeutic avenue to treat currently incurable neurodegenerative diseases. Learn more about us, autophagy and the exciting work we do in this video. #autophagy #neuroscience #drugdiscovery

Samsara is featured in the Daily Telegraph today talking about our exciting candidate drug for Parkinson's Disease: telegraph.co.uk/business/2023/…

We're excited to unveil our promising autophagy drug candidate SAM001 which will be the first agent of its class to enter clinical trials, offering new hope for people with Parkinson’s and Motor Neurone Disease (ALS): samsaratherapeutics.com/samsara-therap…

Excited to see word is spreading about SAM001 our autophagy-inducing drug candidate... pharmaceuticalmanufacturer.media/pharma-manufac…

It was great to chat to BBC Radio Oxford today about autophagy, our Parkinson's disease drug candidates and the support of The Michael J Fox Foundation for Parkinson’s Research. youtube.com/watch?v=uvLnB8…

We're delighted to announce that Prof Dame Pamela Shaw joins Samsara's scientific advisory board to help accelerate our ALS (Motor Neurone Disease) drug development. samsaratherapeutics.com/samsara-therap…

How close are we to autophagy-boosting therapeutics that could reshape the treatment of debilitating age-related diseases? Peter Hamley. our Chief Scientific Officer, shares his thoughts on Longevity Technology longevity.technology/news/from-theo…

Thanks European Pharmaceutical Manufacturer for sharing our thoughts on why we must keep our foot on the gas in the race to find more effective treatments for neurodegenerative diseases. pharmaceuticalmanufacturer.media/pharmaceutical… #leqembi #donanemab #tofersen #neuro #autophagy

We have exciting news – we are FINALISTS of the Best Ermerging Biotech category for the @OBN 2023 #OBNAwards. Join us at The Royal Lancaster in London on November 22nd. Find out more at obn-awards.com #lifesciences #innovation #achievement #celebration

Samsara Therapeutics' CSO Peter Hamley talks to Drug Discovery World about the potential of boosting autophagy in neurodegenerative diseases and beyond: ddw-online.com/turning-scienc…

2023 has brought promising developments in the field of Alzheimer’s - our CSO Peter Hamley chats to Health Tech World about what these mean for patients and why Samsara is keeping its foot on the gas in the search for new treatments: x.com/healthtechworl…

Curious as to how boosting autophagy could help in rare disease treatment? Follow the link to Samsara Chief Scientific Officer, Peter Hamley’s article in Drug Target Review: drugtargetreview.com/article/111762…

Congratulations to Samsara's Catherine Coutts for being selected to give a flash presentation of her poster on our LysoSeeker platform at ELRIG 2023

Thrilled and proud to win the Best Emerging Biotech category at the #OBNAwards! x.com/OBN_UK/status/…